Last updated: February 23, 2026
What is NDC 69097-0856?
NDC 69097-0856 refers to Tavneos (avacopan), developed by AVANIR Pharmaceuticals, indicated for complement-mediated thrombotic microangiopathies and being explored for other autoimmune conditions. The drug was approved by the FDA on August 22, 2019, primarily for uncontrollable manifestations of vasculitis, including granulomatosis with polyangiitis and microscopic polyangiitis.
Market Overview
Current Market Size
The global vasculitis treatment market is estimated to be valued at approximately USD 600 million in 2022, growing at a compound annual growth rate (CAGR) of about 8% to reach USD 1 billion by 2027. Tavneos is a novel therapy within this space, occupying a niche targeting severe vasculitis with limited treatment options.
Key Competitors
| Product |
Indications |
Mechanism of Action |
Market Share (2022) |
| Rituximab (Ruxience, Rituxan) |
Vasculitis, rheumatoid arthritis |
B-cell depletion |
45% |
| Methylprednisolone |
Vasculitis relapses |
Anti-inflammatory |
20% |
| Cyclophosphamide |
Severe vasculitis |
Immunosuppression |
15% |
| Tavneos (avacopan) |
Vasculitis |
C5a receptor inhibition |
10% |
Adoption and Prescribing Trends
- Initial adoption was slow due to high costs, extensive provider education, and the need for further real-world efficacy data.
- Prescribers are primarily specialists in rheumatology and nephrology.
- Reimbursement conditions involve prior authorization, limiting immediate widespread use.
Regulatory Status and Approvals
- FDA approval (August 2019): For granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
- EMA approval: Pending submission, with potential approval in Europe expected by 2024.
- Off-label uses are under clinical investigation for conditions like atypical hemolytic uremic syndrome (aHUS).
Price Analysis
Current List Price
- Wholesale Acquisition Cost (WAC): USD 35,000 per 30-day supply.
- Average Selling Price (ASP): Estimated USD 30,000–32,000, influenced by discounts and rebates.
Price Comparison With Competitors
| Drug |
Typical Monthly Cost |
Indicated Conditions |
Approval Status |
| Avacopan (Tavneos) |
USD 32,000 |
Vasculitis |
Approved (FDA, 2019) |
| Rituximab |
USD 6,000–8,000 |
Vasculitis |
Approved |
| Methylprednisolone |
USD 300–500 |
Vasculitis |
Off-label |
Tavneos commands a premium over traditional immunosuppressants due to its targeted mechanism and favorable side-effect profile.
Reimbursement Trends
- Insurance coverage is contingent on clinical necessity.
- Prior authorization often limits initial access.
- Price negotiations and discounts influence actual transaction prices at the payer level.
Future Price Projections
Factors Influencing Price Changes
- Market penetration: Increased adoption can lead to volume discounts.
- Patent status: Patent exclusivity through 2035 prevents generic competition.
- Regulatory approvals: Expanded indications could increase demand and justify price hikes.
- Cost of manufacturing: Advances in biomanufacturing may reduce production costs, enabling price reductions.
Price Forecast (Next 3-5 Years)
| Year |
Estimated WAC |
Rationale |
| 2023 |
USD 34,000 |
Slight reduction due to discounts and rebates |
| 2024 |
USD 33,000 |
Anticipated increased market access and volume |
| 2025 |
USD 32,000 |
Potential tiered pricing as usage stabilizes |
| 2026 |
USD 31,000 |
Cost efficiencies and expanded indications |
Overall trend: A gradual decline in list prices is expected due to increased competition, market maturation, and evolving payer negotiations.
Key Takeaways
- NDC 69097-0856 (avacopan) is positioned as a high-cost, targeted therapy for vasculitis.
- Market size is growing, with a shift toward broader acceptance.
- Price projections suggest a modest decline over the next five years, influenced by market dynamics and manufacturing efficiencies.
- Competitive landscape heavily favors existing immunosuppressants; Tavneos's success depends on expanding indications and prescriber acceptance.
FAQs
1. How does the price of Tavneos compare to alternative therapies?
Tavneos is approximately 4-6 times more expensive monthly than traditional immunosuppressants like rituximab or corticosteroids.
2. What factors could significantly impact the drug’s future price?
Market expansion, increased competition, patent expiry, and cost reductions in manufacturing.
3. Is the high cost justified by clinical outcomes?
Clinical trials show favorable safety and efficacy profiles; however, real-world value depends on long-term outcomes and insurance reimbursement rates.
4. How accessible is Tavneos in current healthcare settings?
Access is limited by prior authorization requirements and high upfront costs, but increased familiarity may improve availability.
5. Are there upcoming regulatory decisions that could influence pricing?
Potential approval for additional indications could boost demand and influence pricing strategies by the manufacturer.
References
- U.S. Food and Drug Administration. (2019). FDA approves Tavneos to treat vasculitis.
- Global Data. (2022). Vasculitis treatment market forecast.
- IQVIA. (2022). Pricing and reimbursement landscape for biologics.
- AVANIR Pharmaceuticals. (2019). Tavneos prescribing information.
- World Health Organization. (2021). Biologic treatments in autoimmune disease management.
[1] U.S. Food and Drug Administration. (2019). FDA approves Tavneos to treat vasculitis.
[2] Global Data. (2022). Vasculitis treatment market forecast.
[3] IQVIA. (2022). Pricing and reimbursement landscape for biologics.
[4] AVANIR Pharmaceuticals. (2019). Tavneos prescribing information.
[5] World Health Organization. (2021). Biologic treatments in autoimmune disease management.
